Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06336330
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2024-03-22
Brief Title:
Real-world Study on Dapagliflozin Usage in Patients With Heart Failure HF in Germany
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Early Treatment of Heart Failure a Non-interventional Study Program of Patients With Heart Failure and Initiated on Dapagliflozin EVOLUTION-HF DEallEF
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EvolutionHF-DE
Brief Summary:
Heart failure HF is a global public health issue that affects more than 63 million people worldwide this burden is expected to increase substantially as the population ages Despite advancements in treatment a HF diagnosis still leads to significant morbidity and mortality there is also an immense impact on patients health-related quality of life HRQoL Dapagliflozin was recently granted approval for heart failure by the European Commission regardless of ejection fraction and whether the patient has diabetes Real-world observational data are necessary to describe dapagliflozin use in real-world settings in order to assess treatment patterns HF symptoms and their impact on physical limitation HRQoL and work productivity as well as health care utilization of patients treated with dapagliflozin in this setting under local treatment standard conditions in Germany
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None